Antiangiogenic drugs in oncology: A focus on drug safety and the elderly - A mini-review

Gerontology

Volumn 56, Issue 3, 2010, Pages 303-309

  Boehm, S ^a   Rothermundt, C ^a   Hess, D ^a   Joerger, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Adverse events; Angiogenesis; Bevacizumab; Sorafenib; Sunitinib

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; COMBRETASTATIN A4; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IMATINIB; INTERLEUKIN 2; IRINOTECAN; LAPATINIB; LEVOTHYROXINE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VOTRIENT;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANXIETY; ARTERY THROMBOSIS; BLEEDING; BLURRED VISION; BRADYCARDIA; BREAST CANCER; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLOR VISION DEFECT; COLORECTAL CANCER; CONFUSION; CONGESTIVE HEART FAILURE; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL STROMAL TUMOR; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEMOPTYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHYROIDISM; INTESTINE ISCHEMIA; ISCHEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; SHORT SURVEY; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THYROID MEDULLARY CARCINOMA; TORSADE DES POINTES; TREMOR; TUMOR VASCULARIZATION; URINE INCONTINENCE; VENOUS THROMBOEMBOLISM; VISUAL DISORDER;

AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; DRUGS, INVESTIGATIONAL; EUROPE; HUMANS; NEOPLASMS; UNITED STATES;

EID: 77951879926     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000262450     Document Type: Short Survey

References (40)

1. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, et al: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14:7871-7877.
2. Charnley N, Donaldson S, Price P: Imaging angiogenesis. Met hods Mol Biol 2009;467:25-51.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al: Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
6. Gordon MS, Cunningham D: Managing patients treated with bevacizumab combination therapy. Oncology 2005; 969 (suppl 3) : S25-S33. (Pubitemid 41680950)
7. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-2285.
8. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239. (Pubitemid 47299901)
9. Sugrue MM, Kozloff M, Hainsworth J. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC : results from the BRiTE registry (abstract 345). 2007 Gastrointestinal Cancer Symposium, Orlando, 2007.
10. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
11. Raman AK, Lombardo JC, Chandrasekhar R: Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer (abstract 14546). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 5 (suppl).
12. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al: Outcomes for elderly, advanced-stage non smallcell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel : analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
14. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial. Lancet 2006;368:1329-1338. (Pubitemid 44528723)
15. van der Veldt AAM, Boven E, Helgason HH, van WM, Berkhof J, de GG, et al: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99:259-265.
16. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G: Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-228.
17. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al: Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112:2500-2508.
18. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-5212.
19. Templeton A: Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008;19:824-825 (Pubitemid 351461059)
20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64 : 7099-7109. (Pubitemid 39331023)
21. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
23. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, et al: Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008;100:1454-1463.
24. Sloan B, Scheinfeld NS: Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008;9:1324-1335.
25. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-119. (Pubitemid 46332383)
26. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, et al: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) (abstract 5021). J Clin Oncol 2009; 27 (suppl).
27. Nikolinakos P, Heymach JV: The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 2008;3(suppl 2):S131-S134. (Pubitemid 351786743)
28. Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, et al: Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;64:1165-1172.
29. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ: Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer : HORIZON III. Clin Colorectal Cancer 2009;8:59-60.
30. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, et al: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-1009. (Pubitemid 47181370)
31. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, et al: Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer : results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523-2529.
32. Morabito A, Piccirillo MC, Falasconi F, De FG, Del GA, Bryce J, et al: Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases : current status and future directions. Oncologist 2009;14:378-390.
33. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer : results from a phase II study. J Clin Oncol 2008;26:4708-4713.
34. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al: Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer : a phase II study. Lancet Oncol 2007;8:975-984. (Pubitemid 47629888)
35. Hinnen P, Eskens FA: Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-1165. (Pubitemid 46625071)
36. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, et al: Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-1850.
37. 2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-197.
38. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
39. Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, et al: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 (abstract LBA4). J Clin Oncol 2009; 27 (suppl).
40. Rini BI: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-1043. (Pubitemid 46202321)